Validity of the two-signal model for activation of CD28-deficient T lymphocytes: Quantitative characterization of an alternative costimulatory function of dendritic cells

Scandinavian Journal of Immunology

Volumn 53, Issue 4, 2001, Pages 346-356

  Cassell, D J ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Upstate Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN; INTERLEUKIN 2; MONOCLONAL ANTIBODY; T LYMPHOCYTE RECEPTOR ALPHA CHAIN;

ANIMAL CELL; ANTIGEN PRESENTING CELL; ARTICLE; CELL DENSITY; CELL INTERACTION; CELL ISOLATION; CELL PROLIFERATION; CONTROLLED STUDY; DENDRITIC CELL; LYMPHOCYTE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD28; ANTIGENS, CD80; ANTIGENS, CD86; CELL COMMUNICATION; DENDRITIC CELLS; LYMPHOCYTE ACTIVATION; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MODELS, BIOLOGICAL; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 0035060017     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3083.2001.00909.x     Document Type: Article

References (100)

1. A theory of self-nonself discrimination
2. A new analysis of allogeneic interactions
3. Clonal expansion versus functional clonal inactivation: A costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy
4. A 44 kilodalton cell surface homodimer regulates interleukin 2 production by activated human T lymphocytes
5. Role of the CD28 receptor in T-cell activation
6. CD28-mediated signaling costimulates murine T cells and prevents induction of anergy in T cell clones
7. Differential T cell costimulatory requirements in CD28-deficient mice
8. Absence of B7-dependent responses in CD28-deficient mice
9. Limited role of CD28-mediated signals in T helper subset differentiation
10. Skin allograft rejection in CD28-deficient mice
11. CD28-deficient mice generate an impaired Th2 response to Schistosoma mansoni infection
12. Acute graft-versus-host disease without costimulation via CD28
13. CD28 is not required for rejection of unmanipulated syngeneic and autologous tumors
14. T cell responses are governed by avidity and costimulatory thresholds
15. + T cells in vitro
16. Duration of TCR stimulation determines costimulatory requirement of T cells
17. Resting and sensitized T lymphocytes exhibit distinct stimulatory (antigen-presenting cell) requirements for growth and lymphokine release
18. B cells turn off virgin but not memory T cells
19. A quantitative analysis of antigenpresenting cell function: Activated B cells stimulate naive CD4 T cells but are inferior to dendritic cells in providing costimulation
20. The B7/BB1 antigen provides one of several costimulatory signals for the activation of CD4+ T lymphocytes by human blood dendritic cells in vitro
21. Langerhans cells: Functional aspects revealed by in Vivo grafting studies
22. Transplantation tolerance induced by CTLA4-Ig
23. The tissue distribution of the B7-2 costimulator in mice: Abundant expression on dendritic cells in situ and during maturation in vitro
24. The cell surface of mouse dendritic cells: FACS analyses of dendritic cells from different tissues including thymus
25. Properties of mouse CD40: Differential expression of CD40 epitopes on dendritic cells and epithelial cells
26. Co-stimulation of murine CD4 T cell growth: Cooperation between B7 and heat-stable antigen
27. Costimulation of CD28- T lymphocytes by 4-1BB ligand
28. CD43 is a murine T cell costimulatory receptor that functions independently of CD28
29. CD40L is important for induction of, but not response to, costimulatory activity. ICAM-1 as the second costimulatory molecule rapidly up-regulated by CD40L
30. Identification of a costimulatory molecule rapidly induced by CD40L as CD44H
31. Distinct costimulatory molecules are required for the induction of effector and memory cytotoxic T lymphocytes
32. CTLA-4-B7 interaction is sufficient to costimulate T cell clonal expansion
33. Involvement of CD40 ligand-CD40 and CTLA4-B7 pathways in murine acute graft-versus-host disease induced by allogeneic T cells lacking CD28
34. Naive CD28-deficient T cells can initiate but not sustain an in vitro antigen-specific immune response
35. Limiting dilution assays for the determination of immunocompetent cell frequencies. I. Data analysis
36. Direct activation of murine resting T cells by con A or anti-CD3 Ig
37. An intracellular calcium increase and protein kinase C activation fail to initiate T cell proliferation in the absence of a costimulatory signal
38. Cell-cell interactions in the T cell proliferative response. I. Analysis of the cell types involved and evidence for nonspecific T cell recruitment
39. On the extraordinary capacity of allogeneic epidermal Langerhans cells to prime cytotoxic T cells in vivo
40. Reversal of in vitro T cell clonal anergy by IL-2 stimulation
41. Murine B7 antigen provides a sufficient costimulatory signal for antigen-specific and MHC-restricted T cell activation
42. Activation and differentiation requirements of primary T cells in vitro
43. Transfected Drosophila cells as a probe for defining the minimal requirements for stimulating unprimed CD8+ T cells
44. Purified MHC Class I and peptide complexes activate niave CD8+ T cells independently of the CD28/B7 and LFA-1/ICAM-1 costimulatory interactions
45. T cell activation determined by T cell receptor number and tunable thresholds
46. A receptor/cytoskeletal movement triggered by costimulation during T cell activation
47. T lymphocyte costimulation mediated by reorganization of membrane microdomains
48. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: Dependence of T cells, B7 costimulation, and T helper cell 1-associated cytokines
49. The immune response induced in vivo by dendritic cells is dependent on B7-1 or B7-2, but the inhibition of both signals does not lead to tolerance
50. A natural immunological adjuvant enhances T cell clonal expansion through a CD28-independent, interleukin (IL)-2-independent mechanism
51. Cytotoxic T lymphocyte antigen 4 (CTLA4) blockade accelerates the acute rejection of cardiac allografts in CD28-independent mice: CTLA4 can function independently of CD28
52. Differential effects of blockade of CD28-B7 on the development of Th1 or Th2 effector cells in experimental Leshmaniasis
53. T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo
54. Acute graftversus-host reaction can be aborted by blockade of costimulatory molecules
55. Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: Superiority of B7-1 over B7-2 for active tumor immunization
56. T-Cell co-stimulation by the CD28 ligand B7 is involved in the immune response leading to rejection of a spontaneously regressive tumor
57. + T cells in vivo is dependent on CD28 costimulation and inhibited by CTLA-4
58. + T cells
59. Regulation of dendritic cell numbers and maturation by lipopolysaccharaide in vivo
60. Activated B cells express CD28/B7-independent costimulatory activity
61. Distinct roles for B7 costimulation in contact hypersensitivity and humoral immune responses to epipctutaneous antigen
62. Role of bone marrow-derived cells in presenting MHC Class I-restricted tumor antigens
63. The role of chemokines and accessory cells in the immunoregulation of cutaneous leishmaniasis
64. Uptake of Leishmania major amastigotes results in activation and interleukin 12 release from murine skin-derived dendritic cells: Implications for the initiation of anti-Leishmania immunity
65. CD28-deficient mice are highly resistant to collagen-induces arthritis
66. Macrophages, but not dendritic cells, present collagen to T cells
67. T-cell co-stimulation through B7RP-1 and ICOS
68. The LFA-1 ligand ICAM-1 provides an important costimulatory signal for T cell receptor-mediated activation of resting T cells
69. + T lymphocytes
70. Linked recognition of helper and cytotoxic antigenic determinants for the generation of cytotoxic T lymphocytes
71. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation
72. + T-helper and a T-killer cell
73. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4
74. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells
75. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity
76. Tumor cells cotransfected with interleukin-7 and B7.1 genes induce CD25 and CD28 on tumor-infiltrating T lymphocytes and are strong vaccines
77. Enhancement of the anti-tumor immune response using a combination of interferon-γ and B7 expression in an experimental mammary carcinoma
78. Enhancement of antitimor immunity by CTLA-4 blockade
79. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer
80. Enhanced induction of antitumor Tcell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: The effect is manifested only at the restricted tumorbeating stages
81. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma
82. Granulocyte-macrophage colony-stimulating factor is essential for the viability and function of cultured murine epidernal Langerhans cells
83. Immature dendritic cells phagocytose apoptotic cells via αvβ5 and CD36, and crosspresent antigens to cytotoxic T lymphocytes
84. Tumor antigen presentation by murine epidermal cells
85. Peptide-pulsed dendritic cells induce antigen-specific, CTL-mediated protective tumor immunity
86. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo
87. Vaccination of patients with B cell lymphoma using autologous antigen-pulsed dendritic cells
88. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
89. Idiotypic proteinpulsed adherent peripheral blood mononuclear cell-derived dendritic cells prime immune system in multiple myeloma
90. Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides
91. A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen
92. A pilot clinical trial of HIV antigen-pulsed allogeneic and autologous dendritic cell therapy in HIV-infected patients
93. Expansion of a CD8+CD28- cell population in the blood and lung of HIV-positive patients
94. Clonal populations of CD4+ and CD8+ T cells in patients with multiple myeloma and paraproteinemia
95. Phenotype, cytokine production and cytolytic capacity of fresh (uncultured) tumour-infiltrating T lymphocytes in human renal cell carcinoma
96. A pathway of costimulation that prevents anergy in CD28- T cells: B7-independent costimulation of CD1-restricted T cells
97. Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells
98. Impaired CD28-mediated co-stimulation in anergic T cells
99. The role of CTLA-4 in the regulation and initiation of T-cell responses
100. B7-1 engagement of Cytotoxic T lymphocyte antigen 4 inhibits T cell activation in the absence of CD28